Literature DB >> 16844405

Adenosine A(2b) receptor is highly expressed in human hepatocellular carcinoma.

Hong-Jun Xiang1, Zheng-Cai Liu, De-Sheng Wang, Yong Chen, Yan-Ling Yang, Ke-Feng Dou.   

Abstract

High levels of adenosine accumulate in hypoxic tissues during the rapid growth of tumors, suggesting activation of adenosine receptors may facilitate tumor progress. The relevance of adenosine receptors to hepatocellular carcinoma (HCC), in particular the adenosine A(2b) receptor (A(2b)), is not yet fully understood. The aim of this study was to assess whether A(2b) was differentially expressed in normal and cancerous tissues and evaluate the clinicopathological correlation of A(2b) level in HCC. Expression of A(2b) in tumor cells was investigated by immunohistochemical staining. Protein analysis was done by Western blotting and evaluation of A(2b) mRNA expression levels utilized quantitative real-time PCR analysis of tissue samples of 64 hepatocellular carcinomas and in their paired adjacent normal tissues. Western blot data suggested that A(2b) was expressed predominantly in the cell membrane and cytoplasm of tumor cells and that the intensity of A(2b) protein expression was consistently higher in HCC than in adjacent normal tissues. Levels of A(2b) mRNA in HCC were significantly higher than in adjacent tissues, as measured by real-time PCR (P<0.001). With regard to venous invasion, satellite lesions and advanced pathologic Tumor-Node-Metastasis (pTNM) stage, the A(2b) level tended to be higher than that seen in negative cases (P<0.05). Our findings demonstrate that A(2b) expression is up-regulated in HCC, the expression level of A(2b) is correlated to tumor progression in HCC, and suggest that A(2b) may be a novel target for HCC therapeutic strategy.

Entities:  

Year:  2006        PMID: 16844405     DOI: 10.1016/j.hepres.2006.06.008

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  18 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

2.  Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy.

Authors:  A Kalhan; B Gharibi; M Vazquez; B Jasani; J Neal; M Kidd; I M Modlin; R Pfragner; D A Rees; J Ham
Journal:  Purinergic Signal       Date:  2011-11-27       Impact factor: 3.765

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 4.  Targeting A2 adenosine receptors in cancer.

Authors:  David Allard; Martin Turcotte; John Stagg
Journal:  Immunol Cell Biol       Date:  2017-02-08       Impact factor: 5.126

Review 5.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Host A(2B) adenosine receptors promote carcinoma growth.

Authors:  Sergey Ryzhov; Sergey V Novitskiy; Rinat Zaynagetdinov; Anna E Goldstein; David P Carbone; Italo Biaggioni; Mikhail M Dikov; Igor Feoktistov
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

Review 7.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

8.  Downregulation of the adenosine a2b receptor by RNA interference inhibits hepatocellular carcinoma cell growth.

Authors:  Hong-Jun Xiang; Fu-Lu Chai; De-Sheng Wang; Ke-Feng Dou
Journal:  ISRN Oncol       Date:  2011-04-28

9.  Molecular expression of adenosine receptors in OVCAR-3, Caov-4 and SKOV-3 human ovarian cancer cell lines.

Authors:  S Hajiahmadi; M Panjehpour; M Aghaei; S Mousavi
Journal:  Res Pharm Sci       Date:  2015 Jan-Feb

Review 10.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.